Haihe Biopharma News and Activities
Presence
Haihe Biopharma develops biotechnology medicines for cancer and immune diseases. Its main products and services include drug discovery, clinical-stage therapies, and research support for hospitals, patients, and healthcare partners.
Haihe Biopharma products and services overview:
- Cancer therapies
- Immune therapies
- Drug discovery
- Clinical development
- Biologic medicines
Revenue: ~$0 million
Employees: 400
Headquarters: Shanghai, China
Haihe Biopharma is one of the...
Executives
View the org chart displaying its 8 main executives
Most searched biographies at Haihe Biopharma
- Ruiping Dong, Chief Executive Officer
- Jian Ding, Chairman of the Board
- Catherine Gu, Executive Marketing Director
Create your alert
to follow the executive moves at Haihe Biopharma.
Biotechnology
Haihe Biopharma has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).
Popular M&A news in Biotechnology
- Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
- The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
- MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
Popular contacts in Biotechnology
News
Press releases by Haihe Biopharma
- Haihe Biopharma's innovative drug PARP1 inhibitor has obtained clinical trial approval in China
- Haihe Biopharma Enters Into Exclusive License Agreement with Taiho Pharma for PI3Kα Inhibitor Risovalisib (CYH33)
- HaiHe Biopharma's Selective PI3Kα Inhibitor was Granted Orphan Drug Designation in Japan
- Haihe Biopharma Announces that Paclitaxel Oral Solution (RMX3001) was Approved by NMPA as Second-line Treatment for Gastric Cancer
- Haihe Biopharma and Taiho Pharmaceutical Announce the Launch of MET Inhibitor HAIYITAN® Tablets 50mg in Japan
- Haihe Announces First Patient Treated in China in SCC244-G303 Phase III Trial
- An innovative drug Gumarontinib (MET inhibitor) discovered and developed by Haihe Biopharma has been successfully approved in Japan
- Haihe Biopharma Presented results of two clinical studies in 2024 ASCO Annual Meeting
- Haihe Biopharma Announces Preliminary Results from the Phase 1 Part of a First-in-Human Phase I/II Study of EZH1/2 Inhibitor HH2853 in the Epithelioid Sarcoma Population at ASCO Annual Meeting 2023
- Haihe Biopharma Announces Preliminary Results of the First-in-Human Clinical Study of EZH1/2 Inhibitor HH2853 at AACR Annual Meeting 2023
- View more press releases Close
Social media about Haihe Biopharma
- Haihe Biopharma on Wikipedia, Google News & Yahoo Finance
- Haihe Biopharma on LinkedIn, X (Twitter) & YouTube
